Listar por autor 

Listar por autor "Perea Amarillo, Raúl"  

Mostrando ítems 1-4 de 4

    • Artículo
      Icon

      Cut-off ranges of infliximab serum levels in Crohn’s disease in the clinical practice 

      Valdés Delgado, Teresa; Guerra Veloz, María Fernanda; Castro Laria, Luisa; Maldonado Pérez, Belén; Perea Amarillo, Raúl; Merino Bohórquez, Vicente; Sáez, Antonia; Caunedo Álvarez, Ángel; Argüelles Arias, Federico (Aran Ediciones S.A., 2020)
      Introduction: between 30 % and 40 % of patients treated with infliximab lose response during maintenance. Ther apeutic ...
    • Artículo
      Icon

      Evolution of the incidence of inflammatory bowel disease in Southern Spain 

      Chaaro Benallal, Dina; Guerra Veloz, María Fernanda; Argüelles Arias, Federico; Benítez, José Manuel; Perea Amarillo, Raúl; Iglesias, Eva; Vilches Arenas, Ángel; Romero Gómez, Manuel (Aran Ediciones S.A., 2017)
      Background: The incidence of inflammatory bowel disease is increasing in Europe and in Spain. However, there is no recent ...
    • Artículo
      Icon

      Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data 

      Guerra Veloz, María Fernanda; Belvis Jiménez, María Inmaculada; Valdés Delgado, Teresa; Castro Laria, Luisa; Maldonado Pérez, Belén; Perea Amarillo, Raúl; Merino Bohórquez, Vicente; Caunedo Álvarez, Ángel; Vilches Arenas, Ángel; Argüelles Arias, Federico (Original Research, 2019)
      Background: Several studies have reported positive efficacy outcomes for patients with inflammatory bowel disease treated ...
    • Artículo
      Icon

      Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results 

      Argüelles Arias, Federico; Guerra Veloz, María Fernanda; Perea Amarillo, Raúl; Vilches Arenas, Ángel; Castro Laria, Luisa; Maldonado Pérez, Belén; Merino Bohórquez, Vicente; Romero Gómez, Manuel (Lippincott Williams & Wilkins, 2017)
      Background: Biological agents, such as infliximab, have transformed the outcomes of patients with immune-mediated inflammatory ...